CLDI Calidi Biotherapeutics, Inc
Price Chart
Executive Summary
Calidi Biotherapeutics disclosed an audit report with a going-concern emphasis in its 2025 Form 10-K, required by NYSE American Section 610(b). The company, with only a $4M market cap and no approved products, faces a material risk of inability to continue operations without additional capital, and its lead candidate CLD-401 is still in IND-enabling studies. This is a strong negative signal for a pre-revenue biotech with limited cash runway.
Actionable Insight
The going-concern disclosure makes CLDI a high-risk holding. Traders should expect continued downward pressure as the company must raise dilutive capital or face liquidation. Avoid long positions until a material capital infusion or pipeline catalyst materializes. Short interest may already be limited due to tiny float — monitor for OTC delisting.
Key Facts
- Audit report on 2025 10-K includes a going-concern explanatory paragraph
- Lead candidate CLD-401 remains in IND-enabling studies — no near-term revenue
- Market cap is approximately $4M, indicating severe financial distress
- Forward-looking statements explicitly flag inadequate capital to support clinical trials
- Trading on OTC markets (no NYSE American listing gain) suggests non-compliance or delisting risk
- Historical calibration for CLDI reports shows poor win rate (25% T+20) and large negative alpha, consistent with chronic distress bias
Financial Impact
Going-concern qualification implies existential risk for this $4M market cap issuer; no revenue or earnings to quantify
Risk Factors
- Inability to raise sufficient capital to fund operations in the next 12 months
- NYSE American delisting likely (already trading OTC)
- Lead asset (CLD-401) is years from potential approval with high clinical risk
- Ultra-low market cap creates extreme volatility and liquidity constraints
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300394 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 22, 2026
1d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 20, 2026
4w ago
|
Press Release
| $0.2500 $0.1830 | ▼ −26.80% | ▼ −31.00% | $0.1760 (−29.60%) |
|
Mar 27, 2026
8w ago
|
Press Release
| $0.2390 $0.2240 | ▼ −6.28% | ▼ −18.87% | $0.1760 (−26.36%) |
|
Mar 10, 2026
10w ago
|
Press Release
| $0.3600 $0.2480 | ▲ +31.11% | ▲ +30.96% | $0.1760 (+51.11%) |
|
Mar 5, 2026
11w ago
|
Press Release
| $0.3610 $0.2450 | ▼ −32.13% | ▼ −30.09% | $0.1760 (−51.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access